Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients

被引:356
作者
Regidor, Deborah L.
Kopple, Joel D.
Kovesdy, Csaba P.
Kilpatrick, Ryan D.
McAllister, Charles J.
Aronovitz, Jason
Greenland, Sander
Kalantar-Zadeh, Kamyar
机构
[1] Harbor UCLA Med Ctr, Div Nephrol & Hypertens, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA
[2] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA
[4] Dept Vet Affairs, Salem, VA USA
[5] DaVita Inc, El Segundo, CA USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 17卷 / 04期
关键词
D O I
10.1681/ASN.2005090997
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Although treating anemia of chronic kidney disease by erythropoiesis-stimulating agents (ESA) may improve survival, most studies have examined associations between baseline hemoglobin values and survival and ignored variations in clinical and laboratory. measures over time. It is not clear whether longitudinal changes in hemoglobin or administered ESA have meaningful associations with survival after adjustment for time-varying confounders. With the use of time-dependent Cox regression models, longitudinal associations were examined between survival and quarterly (13-wk averaged) hemoglobin values and administered ESA dose in a 2-yr (July 2001 to June 2003) cohort of 58,058 maintenance hemodialysis patients from a large dialysis organization (DaVita) in the United States. After time-dependent and multivariate adjustment for case mix, quarterly varying administered intravenous iron and ESA doses, iron markers, and nutritional status, hemoglobin levels between 12 and 13 g/dl were associated with the greatest survival. Among prevalent patients, the lower range of the recommended Kidney Disease Quality Outcomes Initiative hemoglobin target (11 to 11.5 g/dl) was associated with a higher death risk compared with the 11.5- to 12-g/dl range. A decrease or increase in hemoglobin over time was associated with higher or lower death risk, respectively, independent of baseline hemoglobin. Administration of any dose of ESA was associated with better survival, whereas among those who received ESA, requiring higher doses were surrogates of higher death risk. In this observational study, greater survival was associated with a baseline hemoglobin between 12 and 13 g/dl, treatment with ESA, and rising hemoglobin. Falling hemoglobin and requiring higher ESA doses were associated with decreased survival. Randomized clinical trials are required to examine these associations.
引用
收藏
页码:1181 / 1191
页数:11
相关论文
共 48 条
[11]   Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients [J].
Cotter, DJ ;
Stefanik, K ;
Zhang, Y ;
Thamer, M ;
Scharfstein, D ;
Kaufman, J .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (10) :1086-1095
[12]   Inflammation and resistance to treatment with recombinant human erythropoietin [J].
Del Vecchio, L ;
Pozzoni, P ;
Andrulli, S ;
Locatelli, F .
JOURNAL OF RENAL NUTRITION, 2005, 15 (01) :137-141
[13]   Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients [J].
Drüeke, TB ;
Eckardt, KU .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 :28-31
[14]  
Eckardt KU, 2000, CLIN NEPHROL, V53, pS2
[15]   Use of erythropoietin before the initiation of dialysis and its impact on mortality [J].
Fink, JC ;
Blahut, SA ;
Reddy, M ;
Light, PD .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (02) :348-355
[16]   The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease [J].
Foley, RN ;
Parfrey, PS ;
Harnett, JD ;
Kent, GM ;
Murray, DC ;
Barre, PE .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (01) :53-61
[17]   Role of cytokines in the response to erythropoietin in hemodialysis patients [J].
Goicoechea, M ;
Martin, J ;
De Sequera, P ;
Quiroga, JA ;
Ortiz, A ;
Carreño, V ;
Caramelo, C .
KIDNEY INTERNATIONAL, 1998, 54 (04) :1337-1343
[18]   Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients [J].
Gunnell, J ;
Yeun, JY ;
Depner, TA ;
Kaysen, GA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (01) :63-72
[19]   Time-dependent associations between iron and mortality in hemodialysis patients [J].
Kalantar-Zadeh, K ;
Regidor, DL ;
McAllister, CJ ;
Michael, B ;
Warnock, DG .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (10) :3070-3080
[20]   Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population [J].
Kalantar-Zadeh, K ;
Kopple, JD ;
Kilpatrick, RD ;
McAllister, CJ ;
Shinaberger, CS ;
Gjertson, DW ;
Greenland, S .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (03) :489-500